Adenovirus infections - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Adenovirus infections – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenovirus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Adenovirus infections: Overview
Adenoviruses are common viruses that cause a range of illness. They can cause cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhea, and pink eye (conjunctivitis). Most adenovirus infections are mild with few symptoms. While each child may experience symptoms differently, the most common include: Respiratory infections, Intestinal tract infections. Adenoviruses are contagious, which means an individual can pass them on to the other. The type of infection determines how it spreads. A Physical exam is generally carried for the diagnosis of Adenovirus infections. Certain blood tests may be done to evaluate the infection. These include: blood test, stool test, urine test and swab test. Children often get over the illness on their own within a few days. Some infections, like pink eye or pneumonia, can last for a week or more.
'Adenovirus infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adenovirus infections pipeline landscape is provided which includes the disease overview and Adenovirus infections treatment guidelines. The assessment part of the report embraces, in depth Adenovirus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenovirus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Adenovirus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adenovirus infections Emerging Drugs
Further product details are provided in the report
Adenovirus infections: Therapeutic Assessment
This segment of the report provides insights about the different Adenovirus infections drugs segregated based on following parameters that define the scope of the report, such as:
Adenovirus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adenovirus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenovirus infections drugs.
Adenovirus infections Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Adenovirus infections – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenovirus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Adenovirus infections: Overview
Adenoviruses are common viruses that cause a range of illness. They can cause cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhea, and pink eye (conjunctivitis). Most adenovirus infections are mild with few symptoms. While each child may experience symptoms differently, the most common include: Respiratory infections, Intestinal tract infections. Adenoviruses are contagious, which means an individual can pass them on to the other. The type of infection determines how it spreads. A Physical exam is generally carried for the diagnosis of Adenovirus infections. Certain blood tests may be done to evaluate the infection. These include: blood test, stool test, urine test and swab test. Children often get over the illness on their own within a few days. Some infections, like pink eye or pneumonia, can last for a week or more.
'Adenovirus infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adenovirus infections pipeline landscape is provided which includes the disease overview and Adenovirus infections treatment guidelines. The assessment part of the report embraces, in depth Adenovirus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenovirus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Adenovirus infections R&D. The therapies under development are focused on novel approaches to treat/improve Adenovirus infections.
This segment of the Adenovirus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adenovirus infections Emerging Drugs
- ALVR105 (Viralym-M): Allovir
- Adenovirus-specific T cell therapy: Kuur Therapeutics
Further product details are provided in the report
Adenovirus infections: Therapeutic Assessment
This segment of the report provides insights about the different Adenovirus infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Adenovirus infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Adenovirus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adenovirus infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenovirus infections drugs.
Adenovirus infections Report Insights
- Adenovirus infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Adenovirus infections drugs?
- How many Adenovirus infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adenovirus infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adenovirus infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adenovirus infections and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Adenovirus infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Adenovirus infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Adenovirus infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Adenovirus infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
ALVR105 (Viralym-M): Allovir
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
Adenovirus-specific T cell therapy: Kuur Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Filociclovir: Microbiotix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Adenovirus infections Key Companies
Adenovirus infections Key Products
Adenovirus infections- Unmet Needs
Adenovirus infections- Market Drivers and Barriers
Adenovirus infections- Future Perspectives and Conclusion
Adenovirus infections Analyst Views
Adenovirus infections Key Companies
Appendix
Executive Summary
Adenovirus infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Adenovirus infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Adenovirus infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Adenovirus infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
ALVR105 (Viralym-M): Allovir
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
Adenovirus-specific T cell therapy: Kuur Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Filociclovir: Microbiotix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Adenovirus infections Key Companies
Adenovirus infections Key Products
Adenovirus infections- Unmet Needs
Adenovirus infections- Market Drivers and Barriers
Adenovirus infections- Future Perspectives and Conclusion
Adenovirus infections Analyst Views
Adenovirus infections Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Adenovirus infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Adenovirus infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Adenovirus infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Adenovirus infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
